278 related articles for article (PubMed ID: 27450295)
1. Type-2 cannabinoid receptors in neurodegeneration.
Bisogno T; Oddi S; Piccoli A; Fazio D; Maccarrone M
Pharmacol Res; 2016 Sep; 111():721-730. PubMed ID: 27450295
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease.
Köfalvi A; Lemos C; Martín-Moreno AM; Pinheiro BS; García-García L; Pozo MA; Valério-Fernandes Â; Beleza RO; Agostinho P; Rodrigues RJ; Pasquaré SJ; Cunha RA; de Ceballos ML
Neuropharmacology; 2016 Nov; 110(Pt A):519-529. PubMed ID: 26976670
[TBL] [Abstract][Full Text] [Related]
3. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Fernández-Ruiz J; Romero J; Ramos JA
Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
[TBL] [Abstract][Full Text] [Related]
4. Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB
Ferrisi R; Ceni C; Bertini S; Macchia M; Manera C; Gado F
Pharmacol Res; 2021 Aug; 170():105607. PubMed ID: 34089867
[TBL] [Abstract][Full Text] [Related]
5. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.
Gómez-Cañas M; Morales P; García-Toscano L; Navarrete C; Muñoz E; Jagerovic N; Fernández-Ruiz J; García-Arencibia M; Pazos MR
Pharmacol Res; 2016 Aug; 110():205-215. PubMed ID: 27013280
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective offerings by agmatine.
Kotagale NR; Taksande BG; Inamdar NN
Neurotoxicology; 2019 Jul; 73():228-245. PubMed ID: 31063707
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.
Bisogno T; Di Marzo V
CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):564-73. PubMed ID: 20632970
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid type 2 receptor agonist JWH-133, attenuates Okadaic acid induced spatial memory impairment and neurodegeneration in rats.
Çakır M; Tekin S; Doğanyiğit Z; Erden Y; Soytürk M; Çiğremiş Y; Sandal S
Life Sci; 2019 Jan; 217():25-33. PubMed ID: 30500552
[TBL] [Abstract][Full Text] [Related]
9. Δ
Shang VC; Kendall DA; Roberts RE
Biochem Pharmacol; 2016 Nov; 120():63-71. PubMed ID: 27641813
[TBL] [Abstract][Full Text] [Related]
10. An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration.
Burnstock G
Neuropharmacology; 2016 May; 104():4-17. PubMed ID: 26056033
[TBL] [Abstract][Full Text] [Related]
11. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.
Pertwee RG
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3353-63. PubMed ID: 23108552
[TBL] [Abstract][Full Text] [Related]
12. Cannabis and Endocannabinoid Signaling in Epilepsy.
Katona I
Handb Exp Pharmacol; 2015; 231():285-316. PubMed ID: 26408165
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.
Paloczi J; Varga ZV; Hasko G; Pacher P
Antioxid Redox Signal; 2018 Jul; 29(1):75-108. PubMed ID: 28497982
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoids and Mental Disorders.
Rubino T; Zamberletti E; Parolaro D
Handb Exp Pharmacol; 2015; 231():261-83. PubMed ID: 26408164
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoids in nervous system health and disease: the big picture in a nutshell.
Skaper SD; Di Marzo V
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3193-200. PubMed ID: 23108539
[TBL] [Abstract][Full Text] [Related]
16. PKCβII-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity.
Bellini G; Torella M; Manzo I; Tortora C; Luongo L; Punzo F; Colacurci N; Nobili B; Maione S; Rossi F
Pharmacol Res; 2017 Jan; 115():267-274. PubMed ID: 27919827
[TBL] [Abstract][Full Text] [Related]
17. Role of CB2 receptors in neuroprotective effects of cannabinoids.
Fernández-Ruiz J; Pazos MR; García-Arencibia M; Sagredo O; Ramos JA
Mol Cell Endocrinol; 2008 Apr; 286(1-2 Suppl 1):S91-6. PubMed ID: 18291574
[TBL] [Abstract][Full Text] [Related]
18. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL
J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoidome in neuropsychiatry: Opportunities and potential risks.
Morris G; Walder K; Kloiber S; Amminger P; Berk M; Bortolasci CC; Maes M; Puri BK; Carvalho AF
Pharmacol Res; 2021 Aug; 170():105729. PubMed ID: 34119623
[TBL] [Abstract][Full Text] [Related]
20. Application of Monoterpenoids and their Derivatives for Treatment of Neurodegenerative Disorders.
Volcho KP; Laev SS; Ashraf GM; Aliev G; Salakhutdinov NF
Curr Med Chem; 2018; 25(39):5327-5346. PubMed ID: 28079000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
